ClinicalTrials.gov
public full text
Public Domain
Miltefosine for Children With PKDL
Hypothesis: Primary hypothesis: 1. Oral treatment with Miltefosine in children with PKDL at allometric daily dose (based on body weight and height) for 12 weeks is safe with a cure rate of ≥95%. Secondary hypothesis: 2. Development of PKDL in children and adolescent is genetically predisposed and is associated with IL-10 \& IFN-gamma gene polymorphism causing high and low serum level of IL-10 and IFN-gamma respectively. 3. Nutritional \& environmental factors such as low serum vitamin E, A, D, Zn \& arsenic exposure are associated with PKDL.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis#883177
- Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism#868835
- Weekly Zinc Chelate Supplementation on Children's Growth#847940
- Water-based Zinc Efficacy Trial in Beninese Shool Children#908106
- Heavy metals drinking water contamination and health risk assessment among primary school children of Pakistan#1041660
Record · ID 851031
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive